What is PROCEPT BioRobotics Corporation's market cap?

PROCEPT BioRobotics Corporation (PRCT) has a market capitalization of $1.0B and trades on NASDAQ.

What is PROCEPT BioRobotics Corporation's revenue and profitability?

PROCEPT BioRobotics Corporation generated $322.0M in trailing twelve-month revenue with a net loss of $102.5M, representing a net margin of -31.8%. Gross margin stands at 64.0%, with free cash flow of -$80.6M. These figures are based on the Q1 2026 filing.

Who are PROCEPT BioRobotics Corporation's competitors?

PROCEPT BioRobotics Corporation's key competitors include Intuitive Surgical, Boston Scientific Corporation, Teleflex Incorporated, and others. These companies compete in similar markets and product categories.

Who does PROCEPT BioRobotics Corporation partner with?

PROCEPT BioRobotics Corporation's notable partners include Canadian Imperial Bank of Commerce.

Where is PROCEPT BioRobotics Corporation headquartered?

PROCEPT BioRobotics Corporation is headquartered in United States of America and employs approximately 626 people. It has been publicly traded since 2021.

PROCEPT BioRobotics Corporation

PRCT

PROCEPT BioRobotics is a surgical robotics company that develops and commercializes transformative solutions in urology, specifically for the treatment of benign prostatic hyperplasia (BPH).

Market cap

$1.01B-24.9%

Revenue$322.0M+29.3%

Net income-$102.5M-13.6%

Free cash flow-$80.6M+8.7%

EPS (diluted)-$1.82-7.7%

Trailing twelve months · change vs. prior year

Table of contents

Earnings

Q1 2026 report

April 29, 2026

Revenue$83.1MBeat by $2.6M EPS-$0.56Miss by $0.01

Read the full report

Next report

Aug 4, 2026 (In 6 days)

Revenue estimate$92.6M

EPS estimate-$0.46

Financials

Q1 2026

Income statement

See full

Revenue$83.1M+20.2%

Gross profit$53.9M+22.2%

Operating income-$32.6M-18.8%

Net income-$31.6M-27.9%

EPS (diluted)-$0.56-24.4%

Balance sheet

See full

Cash & equivalents$12.2M-96.2%

Total debt$78.0M-11.8%

Total equity$347.7M-10.7%

Total assets$487.1M-6.2%

Cash flow

See full

Operating cash flow-$38.1M-125%

CapEx$2.9M+58.7%

Free cash flow-$41.0M-118%

Valuation & ratios

Valuation

See full

Market cap$1.01B-24.9%

Enterprise value$1.07B—

P/S3.1×—

Profitability

See full

Gross margin64%+1.3pp

Operating margin-33.9%-3.8pp

Net margin-31.8%-3.4pp

FCF margin-25%-5.7pp

Returns & leverage

See full

Return on equity-27.8%+0.2pp

Debt / equity0.2×0.0×

Current ratio6.7×-2.2×

Segments

By product

See full

Handpieces and other consumables$49.4M+16.2%

System sales and rentals$27.2M+20.8%

Service$6.5M+57.3%

Competitors

By market cap

Intuitive Surgical$127.84B-27.8%

Boston Scientific$67.6B-56.8%

TFX

Teleflex$5.8B+13.6%

PROCEPT BioRobotics Corporation$1.0B—

PDE

Pro-Dex, Inc.$182.8M+4.8%

Apyx Medical Corporation$163.8M+79.1%

Microbot Medical$116.9M+1.6%

Accuray$26.8M-81.3%

By revenue growth

Microbot Medical+62.4%

PROCEPT BioRobotics Corporation+29.3%

TFX

Teleflex+25.0%

Intuitive Surgical+20.7%

Apyx Medical Corporation+18.2%

PDE

Pro-Dex, Inc.+16.4%

Boston Scientific+13.5%

By net margin

Intuitive Surgical28.45%-0.1pp

Boston Scientific17.48%+4.0pp

PDE

Pro-Dex, Inc.16.08%+1.5pp

Apyx Medical Corporation-16.24%+26.3pp

PROCEPT BioRobotics Corporation-31.82%+4.4pp

TFX

Teleflex-47.43%-56.2pp

Microbot Medical-3,669.88%+2,493pp

Profile

PROCEPT BioRobotics is a surgical robotics company that develops and commercializes transformative solutions in urology, specifically for the treatment of benign prostatic hyperplasia (BPH). Its core value proposition is Aquablation therapy, an image-guided, heat-free waterjet ablation process that provides consistent, durable, and safe resection of prostate tissue independent of surgeon experience or prostate size.

Competitive position

PROCEPT holds a unique position as the provider of the only image-guided robotic waterjet therapy for BPH, competing against traditional manual resective surgeries and non-resective implants.

GeographiesUnited States, United Kingdom, Japan, European Union

Customer segmentsHealthcare Providers, Hospitals, Specialized Surgical Centers

Business modelRazor-and-blade, Capital Equipment Sales, Direct Sales

SuppliersSingle-source component suppliers, Ultrasound system manufacturers, Contract sterilization services, Third-party logistics providers

CustomersUrology departments in hospitals, Integrated Delivery Networks (IDNs), Group Purchasing Organizations (GPOs), International distribution partners

CountryUnited States of America

Listed2021

Employees626.0

CEOLarry L. Wood

SectorHealthcare

IndustryMedical - Devices

Websiteprocept-biorobotics.com

FilingsSEC EDGAR

Ask your AI about PROCEPT BioRobotics Corporation.

Connect your AI assistant and dig into the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is PROCEPT BioRobotics Corporation's market cap?: PROCEPT BioRobotics Corporation (PRCT) has a market capitalization of $1.0B and trades on NASDAQ.
What is PROCEPT BioRobotics Corporation's revenue and profitability?: PROCEPT BioRobotics Corporation generated $322.0M in trailing twelve-month revenue with a net loss of $102.5M, representing a net margin of -31.8%. Gross margin stands at 64.0%, with free cash flow of -$80.6M. These figures are based on the Q1 2026 filing.
Who are PROCEPT BioRobotics Corporation's competitors?: PROCEPT BioRobotics Corporation's key competitors include Intuitive Surgical, Boston Scientific Corporation, Teleflex Incorporated, and others. These companies compete in similar markets and product categories.
Who does PROCEPT BioRobotics Corporation partner with?: PROCEPT BioRobotics Corporation's notable partners include Canadian Imperial Bank of Commerce.
Where is PROCEPT BioRobotics Corporation headquartered?: PROCEPT BioRobotics Corporation is headquartered in United States of America and employs approximately 626 people. It has been publicly traded since 2021.